Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

June 15, 2017

Primary Completion Date

March 13, 2020

Study Completion Date

March 31, 2023

Conditions
Breast CancerBreast CarcinomaCancer of BreastMalignant Tumor of Breast
Interventions
DRUG

Palbociclib

Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule

DRUG

Letrozole

Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.

DRUG

Fulvestrant

Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.

PROCEDURE

Optional research biopsy

Patients may consent to paired tumor biopsies at baseline and time of progression.

DRUG

Goserelin

Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.

PROCEDURE

Research blood draw

"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):~* Baseline~* C1D15~* C2D1~* Every 2-3 months thereafter (to coincide with imaging studies)~* Time of progression"

PROCEDURE

Circulating tumor cell blood draw

-Baseline, cycle 2 day 1, post 2 or 3 months of therapy (to coincide with first tumor imaging), and progression

PROCEDURE

Tumor biopsy (optional)

-Baseline and progression

Trial Locations (2)

63110

Washington University School of Medicine, St Louis

68588

University of Nebraska, Lincoln

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Washington University School of Medicine

OTHER

NCT03007979 - Alternative Dosing Schedule of Palbociclib in Metastatic Hormone Receptor Positive Breast Cancer | Biotech Hunter | Biotech Hunter